Last edition
News about "relapsed Small Cell Lung Cancer (SCLC)"
Ris-Rez Cuts Risk of Death by 54 Percent vs Topotecan in Relapsed SCLC in China
Ris-Rez reduced the risk of death by 54 percent versus topotecan in relapsed SCLC in China, extending median overall survival to 18.5 months versus 10.3 months with comparator.
Relapsed Small Cell Lung Cancer (SCLC) | 15/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members